Want to see POM full AI Analyst Report?
POM Stock Chart & Stats
$0.31
--
Market closed
$0.31
--
Day’s Range― - ―
52-Week Range$0.63 - $115.74
Previous CloseN/A
VolumeN/A
Average Volume (3M)2.20M
Market Cap
$5.29M
Enterprise Value$505.22M
Total Cash (Recent Filing)$2.11B
Total Debt (Recent Filing)$37.66B
Price to Earnings (P/E)―
Beta0.90
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding6,774,573
10 Day Avg. Volume781,994
30 Day Avg. Volume2,198,746
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)-4.75
Price to Sales (P/S)5.39
P/FCF Ratio-14.43
Enterprise Value/Market Cap95.43
Enterprise Value/Revenue0.01
Enterprise Value/Gross Profit0.02
Enterprise Value/Ebitda0.07
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Top-line GrowthConsistent revenue expansion (~17% YoY in 2025) indicates durable market demand for PomDoctor’s services and gives management scope to scale platform economics. Over 2–6 months this supports continued investment in product, partnerships and market expansion to pursue margin improvement and service diversification.
Strategic Pivot To AI InfrastructureThe shift to an AI-driven predictive healthcare infrastructure is a structural strategic change. Building an integrated ecosystem (wearables, analytics, physician services, payor links) can create a data flywheel and multi-sided network effects, strengthening competitive positioning and recurring revenue potential over the medium term.
R&D Investment & Capital AccessA large rise in R&D spend and an IPO that improves capital access signals management is funding long-term product and AI capability build-out. Sustained investment can create proprietary data, software and clinical integration advantages that underpin durable differentiation if execution maintains focus and ROI discipline.
Bears Say
Weak Balance SheetPersistent negative equity and rising absolute debt materially constrain financial flexibility. This elevates refinancing, covenant and solvency risk, limits capacity to fund operations organically, and increases reliance on external capital or dilution — a structural constraint on strategic optionality over coming months.
Severe Cash BurnA sharp step-up in cash burn in 2025 creates a recurring funding requirement. Sustained negative operating and free cash flow raises near-term financing and dilution risk, can force reprioritization of initiatives, and undermines ability to steadily scale the new AI platform without further capital raises or cost reduction.
Negative Profitability & Low MarginsLow gross margins and widening operating and net losses indicate the business has not yet translated growth into sustainable profitability. Structural margin pressure limits reinvestment capacity and prolongs the path to self-funded expansion, making long-term viability sensitive to execution, pricing and cost control.
PomDoctor Ltd. Unsponsored ADR News
POM FAQ
What was PomDoctor Ltd. Unsponsored ADR’s price range in the past 12 months?
PomDoctor Ltd. Unsponsored ADR lowest stock price was $0.63 and its highest was $115.74 in the past 12 months.
What is PomDoctor Ltd. Unsponsored ADR’s market cap?
PomDoctor Ltd. Unsponsored ADR’s market cap is $5.29M.
When is PomDoctor Ltd. Unsponsored ADR’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were PomDoctor Ltd. Unsponsored ADR’s earnings last quarter?
Currently, no data Available
Is PomDoctor Ltd. Unsponsored ADR overvalued?
According to Wall Street analysts PomDoctor Ltd. Unsponsored ADR’s price is currently Overvalued.
Does PomDoctor Ltd. Unsponsored ADR pay dividends?
PomDoctor Ltd. Unsponsored ADR does not currently pay dividends.
What is PomDoctor Ltd. Unsponsored ADR’s EPS estimate?
PomDoctor Ltd. Unsponsored ADR’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PomDoctor Ltd. Unsponsored ADR have?
PomDoctor Ltd. Unsponsored ADR has 6,774,573 shares outstanding.
What happened to PomDoctor Ltd. Unsponsored ADR’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of PomDoctor Ltd. Unsponsored ADR?
Currently, no hedge funds are holding shares in POM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PomDoctor Ltd. Unsponsored ADR
Pomdoctor Limited, operating through its various divisions, runs an e-commerce platform for the direct sale of pharmaceutical products to consumers. The company is actively developing an online healthcare services platform specifically designed for managing long-term illnesses within the Chinese market. Its primary emphasis is on chronic disease care and pharmaceutical provision, facilitating a digital portal that connects patients with medical professionals and essential medications. Pomdoctor's operations largely encompass both a virtual hospital model and a comprehensive pharmaceutical supply chain, thus linking individual users, pharmacies, distributors, medical experts, and other healthcare stakeholders. This enterprise was established in 2010 and is headquartered in Guangzhou, China.
Technical Analysis
Ownership Overview
―
Insiders
―
Mutual Funds
0.17% Other Institutional Investors
99.83% Public Companies and
Individual Investors